Cerebrospinal fluid (CSF) pharmacokinetics of intraventricular vancomycin in patients with staphylococcal ventriculitis associated with external CSF drainage

被引:40
作者
Pfausler, B
Haring, HP
Kampfl, A
Wissel, J
Schober, M
Schmutzhard, E
机构
[1] UNIV INNSBRUCK HOSP,DEPT NEUROL,A-6020 INNSBRUCK,AUSTRIA
[2] UNIV INNSBRUCK HOSP,CENT LABS,A-6020 INNSBRUCK,AUSTRIA
关键词
D O I
10.1086/513756
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We studied the efficacy and pharmacokinetics of intraventricularly administered vancomycin in three patients with shunt-associated staphylococcal ventriculitis. We instilled 10 mg of the drug intraventricularly every 24 hours. Cerebrospinal fluid (CSF) levels were measured 1 hour after instillation and then every 2 hours. Peak vancomycin levels reached a mean of 292.9 mu g/mL. The mean trough levels, measured immediately before readministration of vancomycin, were 7.6 mu g/mL; this level has proved to be sufficient for maintaining the necessary steady-state serum concentration of vancomycin. All three patients were cured clinically and bacteriologically, and CSF parameters returned to normal within 5-13 days. No side effects were observed, Our results suggest that intraventricularly administered vancomycin is a valuable therapeutic strategy for treating shunt-associated staphylococcal ventriculitis. In addition, we provide evidence that 10 mg of vancomycin, administered intraventricularly every 24 hours, allows maintenance of therapeutic drug levels in the CSF for at least 24 hours.
引用
收藏
页码:733 / 735
页数:3
相关论文
共 10 条
  • [1] ACCUMULATION OF VANCOMYCIN AFTER INTRAVENTRICULAR INFUSIONS
    ARROYO, JC
    QUINDLEN, EA
    [J]. SOUTHERN MEDICAL JOURNAL, 1983, 76 (12) : 1554 - 1555
  • [2] INTRAVENTRICULAR VANCOMYCIN IN THE TREATMENT OF VENTRICULITIS ASSOCIATED WITH CEREBROSPINAL-FLUID SHUNTING AND DRAINAGE
    BAYSTON, R
    HART, CA
    BARNICOAT, M
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1987, 50 (11) : 1419 - 1423
  • [3] Cooper GL., 1986, Vancomycin: A Comprehensive Review of 30 Years of Clinical Experience
  • [4] FEKETY R, 1990, PRINCIPLES PRACTICE, P317
  • [5] GUMP DW, 1981, REV INFECT DIS, V3, pS289
  • [6] MCLAURIN R L, 1987, Reviews of Infectious Diseases, V9, P595
  • [7] *NAT COMM CLIN LAB, 1984, US EV PREC PERF CLIN, V4
  • [8] KINETICS OF INTRAVENTRICULAR VANCOMYCIN IN INFECTIONS OF CEREBROSPINAL-FLUID SHUNTS
    REESOR, C
    CHOW, AW
    KUREISHI, A
    JEWESSON, PJ
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1988, 158 (05) : 1142 - 1143
  • [9] AUTOMATED FLUORESCENCE POLARIZATION IMMUNOASSAY FOR MONITORING VANCOMYCIN
    SCHWENZER, KS
    WANG, CHJ
    ANHALT, JP
    [J]. THERAPEUTIC DRUG MONITORING, 1983, 5 (03) : 341 - 345
  • [10] SEUFERT RJ, 1990, HOSP PHARM, V25, P849